Single Invitation for PSA Screening Cuts Prostate Cancer Deaths
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- A single invitation for prostate-specific antigen (PSA) screening is associated with reduced prostate cancer deaths, although the absolute reduction is small, according to a study published online April 6 in the Journal of the American Medical Association to coincide with the 39th Annual European Association of Urology Congress, held from April 5 to 8 in Paris.
Richard M. Martin, B.M., B.S., Ph.D., from the University of Bristol in the United Kingdom, and colleagues examined the effect of a single invitation for PSA screening on prostate cancer-specific mortality in a secondary analysis of the Cluster Randomized Trial of PSA Testing for Prostate Cancer involving men aged 50 to 69 years. Ninety-eight percent of the 415,357 eligible men were included in the analyses.
In the intervention and control groups, 12,013 and 12,958 men had a prostate cancer diagnosis (15-year cumulative risk, 7.08 and 6.94 percent, respectively). The researchers found that 0.69 and 0.78 percent of men in the intervention and control groups, respectively, died of prostate cancer at a median 15-year follow-up (rate ratio, 0.92). The PSA screening intervention increased detection of low-grade and localized disease compared with control. All-cause deaths did not differ significantly between the groups (23.2 and 23.3 percent in the intervention and control groups, respectively). Overall, 0.7 and 0.5 percent of prostate cancer deaths in the intervention and control groups, respectively, were related to a diagnostic biopsy or prostate cancer treatment.
"Policymakers considering screening for prostate cancer should consider this small reduction in deaths against the potential adverse effects associated with overdiagnosis and overtreatment of prostate cancer," the authors write.
Two authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.